Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-cell depletion and clinical response to rituximab in rheumatoid arthritis
2014-000859-91Phase 4Completed
- Sponsor
- CHRU Tours
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in rheumatoid arthritis (RA), sponsored by CHRU Tours. Primary endpoint: Clinical response at week 16 and CD4+ T-cell evolution. Started Jun 2015; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2014-000859-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000859-91.